% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Feb 16, 2014 3:50 PM Flag

    Wedbush predicts phase 3-enabling results? And that's a bad thing?

    If the results are inconclusive, there would be no need for a phase 3, Arikace would be dead for NTM. But, if they are positive, Insmed's assertion has always been that the FDA could consider that data set for approval. I wonder if somebody told Wade at Wedbush that Insmed was going to report "bad" CF extension study data. That's the only variable that could change the equation for Insmed's near-term profit potential. I wonder if that someone has any clue of the "actual" data ahead of time? I wonder if Wade could be prosecuted for insider trading if the news comes out negative? Something really stinks about Wedbush's sudden reversal of analysis and maybe it's just cold feet, hopefully not something more serious. CF data will be reported this week, and a positive outcome would be a huge boost for Insmed. I find it interesting that Insmed wants to combine the NTM and CF data in its bid for approval in the EU and it would appear in the US as well. They are attempting to "shoot the moon!"

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The question was timing. Why have this downgrade as INSM was doing an updated presentation (at leerink) and had the production partnership announcement? Adam F published his negative remarks in October when Insmed could not respond. Same thing is now happening here (quiet period). Also, what choice did Wedbush have? Get on the band wagon with all the other upgrades or be a contrarion (think Terry_Insm). They already have been "right" by taking us down almost 16% and having one large owner sell out (planned maybe). One last item, they probably are not involved in any "negotiations" or possible new funding plans for another 5M shares. So, they had nothing to gain here anymore. If he(Wade) is right though with some kind of negative result, then Wedbush should be reported for pre-knowledge of an announcement and using it to their advantage. For now, most everyone else disagrees. We shall see soon enough. Less

      Sentiment: Buy

14.06-0.01(-0.07%)Oct 25 4:00 PMEDT